-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Amlitelimab in Atopic Dermatitis (Atopic Eczema)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Amlitelimab in Atopic Dermatitis (Atopic Eczema) Drug Details: Amlitelimab (KY-1005) is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Amlitelimab in Hidradenitis Suppurativa
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Amlitelimab in Hidradenitis Suppurativa Drug Details: Amlitelimab (KY-1005) is under development for the treatment of...
-
Product Insights
Hidradenitis Suppurativa – Drugs In Development, 2023
Global Markets Direct’s, ‘Hidradenitis Suppurativa - Drugs In Development, 2023’, provides an overview of the Hidradenitis Suppurativa pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hidradenitis Suppurativa, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Hemophilia A (Factor VIII Deficiency) – Drugs In Development, 2023
Global Markets Direct’s, ‘Hemophilia A (Factor VIII Deficiency) - Drugs In Development, 2023’, provides an overview of the Hemophilia A (Factor VIII Deficiency) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hemophilia A (Factor VIII Deficiency), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Malaria – Drugs In Development, 2023
Global Markets Direct’s, ‘Malaria - Drugs In Development, 2023’, provides an overview of the Malaria pipeline landscape. The report provides comprehensive information on the therapeutics under development for Malaria, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Graft Versus Host Disease (GVHD) – Drugs In Development, 2023
Global Markets Direct’s, ‘Graft Versus Host Disease (GVHD) - Drugs In Development, 2023’, provides an overview of the Graft Versus Host Disease (GVHD) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Graft Versus Host Disease (GVHD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Bone Marrow Transplant Rejection – Drugs In Development, 2023
Global Markets Direct’s, ‘Bone Marrow Transplant Rejection - Drugs In Development, 2023’, provides an overview of the Bone Marrow Transplant Rejection pipeline landscape. The report provides comprehensive information on the therapeutics under development for Bone Marrow Transplant Rejection, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Carenoprazan Hydrochloride in Duodenal Ulcer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Carenoprazan Hydrochloride in Duodenal Ulcer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Carenoprazan Hydrochloride in Duodenal Ulcer Drug Details: Carenoprazan hydrochloride is a...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Funobactam in Ventilator Associated Pneumonia (VAP)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Funobactam in Ventilator Associated Pneumonia (VAP) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Funobactam in Ventilator Associated Pneumonia (VAP)Drug Details:XNW-4107 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MRNA-1365 in Respiratory Syncytial Virus (RSV) Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MRNA-1365 in Respiratory Syncytial Virus (RSV) Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.MRNA-1365 in Respiratory Syncytial Virus (RSV) InfectionsDrug Details:mRNA-1365 is under...